Recruiting
Phase 3

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Sponsor:

H. Lundbeck A/S

Code:

NCT05897320

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Eptinezumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information